Cargando…
Plasma YKL-40 in the spectrum of neurodegenerative dementia
BACKGROUND: Increased plasma YKL-40 has been reported in Alzheimer’s disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias. METHODS: YKL-40 was quantified in the plasma of 315 cases, in...
Autores principales: | Villar-Piqué, Anna, Schmitz, Matthias, Hermann, Peter, Goebel, Stefan, Bunck, Timothy, Varges, Daniela, Ferrer, Isidre, Riggert, Joachim, Llorens, Franc, Zerr, Inga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624942/ https://www.ncbi.nlm.nih.gov/pubmed/31299989 http://dx.doi.org/10.1186/s12974-019-1531-3 |
Ejemplares similares
-
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease
por: Zerr, Inga, et al.
Publicado: (2021) -
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017) -
Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers
por: Hermann, Peter, et al.
Publicado: (2022) -
Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
por: Canaslan, Sezgi, et al.
Publicado: (2021) -
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)